University of Nottingham

Scientists at the University of Nottingham have developed a cryogenic mass spectrometry approach that reveals the precise structure and molecular orientation within lipid nanoparticles used in RNA therapeutics.

Precision medicine company Oncimmune Holdings has entered administration after failing to secure a buyer for its German subsidiary or raise additional capital to meet short-term funding needs.

University of Nottingham initiates groundbreaking TrueBlue trial using AI and virtual avatar technology to detect early-stage postnatal depression, offering a modern alternative to traditional clinical scales.

The upcoming TERZO trial will assess duvelisib against standard chemotherapy in patients with nodal T-cell lymphoma with follicular helper T phenotype, addressing a significant treatment gap in rare lymphomas.

• The phase 3 FALCON trial's final overall survival (OS) analysis showed no significant difference between fulvestrant and anastrozole in endocrine therapy-naive, HR-positive advanced breast cancer. • Median OS was 44.8 months for fulvestrant versus 42.7 months for anastrozole (HR, 0.97; P = .76), with a median follow-up of 37.1 months. • A trend toward improved survival with fulvestrant was observed in patients with nonvisceral disease (median OS 65.2 months vs 47.8 months; HR, 0.85). • Post-hoc analysis revealed greater OS improvement with fulvestrant in nonvisceral vs. visceral disease subgroups compared to anastrozole.

• A new study suggests GLP-1 receptor agonists (GLP-1 RAs) may reduce alcohol consumption by targeting the brain's reward center. • The effect was more pronounced in heavy drinkers with obesity (BMI over 30), indicating a potential therapeutic benefit in this population. • Clinical trials and observational studies showed GLP-1 RA use was associated with reduced alcohol consumption and fewer alcohol-related health issues. • These findings suggest GLP-1 RAs could be a future treatment option for excessive alcohol use, potentially reducing alcohol-related deaths.

• The Welsh NHS has reported a 13% increase in prostate cancer detection using the IBEX Galen AI platform during initial pilot studies at Betsi Cadwaladr Health Board. • The successful AI diagnostic tool will be expanded to five additional health boards across Wales and extended to include breast cancer screening applications. • The implementation is part of Wales' new digital health strategy, prioritizing AI-powered diagnostics to improve early detection and streamline cancer diagnosis workflows.